Genezen, a leading cell and gene therapy Contract Development and Manufacturing Organization (CDMO), today announced licensing of the Cytegrity™ proprietary ­­­­stable production system from biotechnology leader CSL. Cytegrity™ is an advanced inducible stable producer technology designed for the production of lentiviral vectors (LVVs). This cutting-edge technology allows for scalable and cost-effective generation of LVVs at clinically effective titers for both gene and cell therapies. Validated through early clinical testing, Cytegrity™ has demonstrated safety and efficacy....